Mineralys Therapeutics, Inc. Common Stock
MLYSStock
$27.08+81.62%52W
Market Cap$2.40B
P/E—
Div yield—
Beta0.59
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-32.28%
Price vs S&P 500 (4W)14.44%
VGM Score53.05
Market Capitalization$2.40B
Earnings Surprise History
Q1 26-0.47est. -0.47
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.20
4.19
4.19
4.19
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MLYSMineralys Therapeutics, Inc. Common Stock | — | — | C | $27.08 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing lorundrostat, a selective aldosterone synthase inhibitor for treatment-resistant hypertension. The orally administered drug targets abnormally elevated aldosterone levels in patients who have not responded to multiple existing antihypertensive therapies.